Streetbeat News

Stock Prices

CBAY

GILD

ICPT

Gilead Sciences Inc (GILD) has agreed to acquire CymaBay Therapeutics Inc (CBAY) for $4.3 billion, aiming to enhance its liver disease portfolio with CymaBay's seladelpar for primary biliary cholangitis (PBC). Despite the acquisition not being a major game-changer for Gilead, it's seen as a low-risk move that leverages Gilead's strong commercial capabilities in liver diseases. Seladelpar's potential in addressing pruritus could differentiate it in the PBC market. Baird maintains a Neutral rating on GILD with an $80 price target.

Portfolio Pulse from Vandana Singh

February 13, 2024 | 7:05 pm

ICPUSD

Internet Computer (CRYPTO: ICP) has seen a price decrease of 3.35% in the last 24 hours, now at $12.91, despite a weekly uptrend of 5.0%. Its trading volume increased by 31.0%, and the circulating supply slightly rose by 0.02% to 458.34 million. Currently, ICP ranks #18 with a market cap of $5.91 billion.

Portfolio Pulse from Benzinga Insights

February 13, 2024 | 7:03 pm

OPUSD

Optimism's (CRYPTO: OP) price has decreased by 4.91% in the last 24 hours to $3.69, despite a 13.0% increase over the past week. The trading volume for OP has decreased by 23.0%, while its circulating supply has increased by 0.22%, reaching 957.38 million. Currently, OP's market cap ranks #28 at $3.53 billion.

Portfolio Pulse from Benzinga Insights

February 13, 2024 | 7:02 pm

LTCUSD

Litecoin (CRYPTO: LTC) has seen a decrease of 5.7% in its price over the last 24 hours, now at $68.58, continuing a week-long downward trend. Despite a significant increase in trading volume by 145%, the circulating supply has slightly decreased. Litecoin's market cap ranks it 21st at $5.08 billion.

Portfolio Pulse from Benzinga Insights

February 13, 2024 | 7:02 pm

UPXI

Upexi (NASDAQ:UPXI) is scheduled to release its quarterly earnings report on February 14, 2024, with an expected EPS of $-0.05. Analysts and investors are keen on not just the earnings beat or miss but also the company's guidance for future growth. Historically, Upexi's share price has reacted to its earnings performance, with a notable 4.0% drop after missing EPS last quarter. The stock has been trading at $1.21 as of February 12, marking a 70.91% decline over the last 52 weeks, indicating a bearish outlook from long-term shareholders.

Portfolio Pulse from Benzinga Insights

February 13, 2024 | 7:02 pm

SANW

S&W Seed (NASDAQ:SANW) is scheduled to release its quarterly earnings report on February 14, 2024, with an expected EPS of $-0.11. Historical performance shows mixed reactions to earnings reports, with the last quarter's miss resulting in a 3.82% share price drop. Over the past year, SANW shares have declined by 67.85%, indicating potential investor concern ahead of the earnings announcement.

Portfolio Pulse from Benzinga Insights

February 13, 2024 | 7:02 pm

AYTU

Aytu BioPharma (NASDAQ:AYTU) is scheduled to release its quarterly earnings report on February 14, 2024, with analysts expecting an EPS of $-0.25. The company's past performance shows a mixed impact on its stock price following earnings announcements, with shares currently trading at $2.93, reflecting a 2.35% decline over the last 52 weeks. Investors are looking for a beat on the EPS estimate and positive guidance for the next quarter.

Portfolio Pulse from Benzinga Insights

February 13, 2024 | 7:02 pm

IPW

iPower (NASDAQ:IPW) is scheduled to release its quarterly earnings report on February 14, 2024, with an expected EPS of $-0.05. Analysts and investors will be looking for the company to beat this estimate and provide positive guidance for the next quarter. iPower's past earnings performance shows a mixed impact on its stock price, with the last quarter's beat followed by a 9.25% drop. Shares are currently trading at $0.59, down 22.68% over the last year, indicating a negative sentiment among long-term shareholders.

Portfolio Pulse from Benzinga Insights

February 13, 2024 | 7:02 pm

AEMD

Aethlon Medical (NASDAQ:AEMD) is scheduled to release its quarterly earnings report on February 14, 2024, with an expected EPS of $-1.23. Historically, the company has had mixed results in beating EPS estimates, with a notable 7.55% share price increase following last quarter's earnings beat. However, shares have declined 67.61% over the last year, indicating bearish sentiment among long-term shareholders. Investors will be keenly watching for not only the earnings outcome but also the company's future guidance.

Portfolio Pulse from Benzinga Insights

February 13, 2024 | 7:01 pm

MMLP

Martin Midstream Partners (NASDAQ:MMLP) is expected to report a Q4 earnings per share (EPS) of $-0.04 on February 14, 2024. Analysts and investors will be looking for an earnings beat and positive guidance for future growth. The company's stock performance has been negative over the last year, with a 20.38% decrease, indicating bearish sentiment among long-term shareholders.

Portfolio Pulse from Benzinga Insights

February 13, 2024 | 7:01 pm